EcoDrugPlus

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSSVLG00005021549
Gene Symbol: IDO1
1 Cross references
98 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSSVLG00005018109
Gene Symbol: IKBKB
1 Cross references
197 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSSVLG00005006574
Gene Symbol: IMPDH1
1 Cross references
333 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSSVLG00005017627
Gene Symbol: IMPDH2
1 Cross references
200 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSSVLG00005017670
Gene Symbol: INPP5D
1 Cross references
213 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSSVLG00005002096
Gene Symbol: IGF1R
1 Cross references
274 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSSVLG00005025555
Gene Symbol: INSR
1 Cross references
288 Possible Orthologues:

Integrin Subunit Alpha 2b

Ensembl ID : ENSSVLG00005000827
Gene Symbol: ITGA2B
1 Cross references
189 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSSVLG00005021071
Gene Symbol: ITGA4
1 Cross references
236 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSSVLG00005001034
Gene Symbol: ITGA5
1 Cross references
269 Possible Orthologues:

Integrin Subunit Alpha V

Ensembl ID : ENSSVLG00005023712
Gene Symbol: ITGAV
1 Cross references
243 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSSVLG00005023311
Gene Symbol: ITGB1
1 Cross references
298 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).